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Abstract 
Objective: To compare the prostaglandin E2 (PGE2) levels of gingival crevicular fluid in 
generalized chronic periodontitis between healthy and type 2 diabetic patients. Material and 
Methods: 56 diabetic and non-diabetic participants with generalized chronic periodontitis were 
selected randomly. They were divided into two groups (G1: generalized chronic periodontitis 
patients with normal blood sugar; and G2: generalized chronic periodontitis patients with 
diabetes). Gingival crevicular fluid samples were obtained from both groups. The average of 2 
samples per day were centrifuged in a laboratory at 2500 rpm and temperature of 4°C for 5 
minutes and placed in a refrigerator at -20°C. The level of PGE2 was measured using ELISA and 
Abcam kit. Data were analyzed by Kolmogorov-Smirnov, Mann-Whitney U Test, Pearson and 
independent T tests. The significant amount was considered 0.05 in this test (α<0.05). Results: 
The mean level of PGE2 was significantly different in the two groups and the mean level of 
PGE2 in the control group was lower than the case group. There was no statistically significant 
relationship between PGE2 with pocket depth, fasting blood sugar (FBS) and HBA1C (p>0.05). 
Conclusion: PGE2 level of diabetic patient group with chronic generalized periodontitis was 
significantly more than non-diabetic group with generalized chronic periodontitis. 
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Introduction 
Periodontitis is a periodontal inflammation that destroys connective tissue attachment of the 
tooth. Periodontitis can be occurred in three main forms: chronic, aggressive and as a manifestation 
of a systemic disease. Chronic periodontitis is the most common form of this disease and generalized 
form involves more than 30% of dentition [1]. 
The condition is started by pathogenic microbes in dental plaque. The microbial challenge by 
the sub gingival biofilm causes recruitment of immune cells into the periodontium, which produces 
cytokines and inflammatory mediators. Several types of prostaglandins (as PGE2) are known 
inflammatory mediators implicated in periodontal disease pathogenesis. PGE2 causes vasodilatation, 
increased vascular permeability and consequently regulate the production of osteoclast activating 
factor thus facilitating bone destruction [2]. 
PGE2 levels, which is identified in gingival crevicular fluid (GCF) of patients with 
periodontal disease, is higher than periodontally healthy subjects and also PGE2 concentration in 
GCF is valuable for predicting periodontitis progression. PGE2 levels in human periodontal disease 
using radioimmunoassay was found 10 times greater than of PGE2 in diseased as compared to 
healthy tissue [3]. 
Diabetes is a metabolic disorder characterize by chronic hyperglycemia reduced insulin 
production, impair insulin act, cause breakdown of glucose transfer from blood into the tissues, 
which sequentially results in high blood glucose levels. Change in the host immunoinflammatory 
reaction to pathogens plays a major role. Diabetes may cause damage adherence, chemotaxis and 
phagocytosis of neutrophil, which ease bacterial persistence in the periodontal pocket and 
considerably increase periodontal damage [4]. There is evidence that suggests that dysregulation of 
prostaglandin contribute to delay in wound healing [5]. 
In recent study, type 1 diabetics and non-diabetics were compared and it was established that 
the PGE2, IL-1β and TNFα levels in GCF were 2-3 times more in diabetics than in non-diabetics 
[6]. The high PGE2 and IL-1β in GCF of type 1 diabetic patients may be a result of a systemic 
reaction and manifestation of gram-negative infections such as periodontal diseases can cause more 
severe periodontal condition [7]. 
Since no study similar to present research has ever been conducted in Iran and considering 
the fact that both diabetes and periodontitis are multifactorial diseases, which can be affected by 
many factors such as genetics, hence the purpose of present case control study was to investigate 
PGE2 levels in gingival fluid in individuals with periodontitis and diabetes. 
 
Material and Methods 
Study Design 
The case-control study was accompanied at the Department of Periodontology of Dental 
Faculty of Tabriz University of Medical Sciences during nine months from October (2015) to June, 
(2016). 
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Study Population 
The target population included 56 persons suffering from chronic generalized periodontitis 
with and without diabetes. In choosing the patient's attention was taken for the existence of 
periodontitis, not to have any systhemic problem excepting diabetes mellitus type 2, to have 
minimum ≥5mm periodontal pocket depth and minimum of 15 teeth, not to have an antibiotic and 
antiinflammatory drugs and periodontal therapy in last 6 months. 
Any periodontal treatment was not done to sampling site so it would not affect the present 
periodontal status. Also no recomendation was given to modifey their oral care. Periodontal Pocket 
Depth (PPD) was determined by using a Williams probe. All measurements were done on all teeth at 
6 sides (distobuccal, buccal, mesiobuccal, distolingual, lingual and mesiolingual) and documented as 
millimeter. 
 
Collecting Gingival Crevicular Fluid (GCF) 
Gum tracheal fluid of patients was collected from diabetic and non-diabetic patients. Relative 
isolation was carried out with cotton roll. Two minutes after ensuring isolation, the sampling of oral 
salivary was carried out by placing the paper cone #25 in sulcus at a depth of 3 mm for each selected 
case with 15-19 paper cones in the area and 3 minutes later paper cones were removed and the paper 
cones that were contaminated with blood were removed from samples (due to the inflammation of 
the sampling area, more paper cones were contaminated with blood and an average of 11 paper cones 
were transferred to the vials) and the rest of paper cones containing GCF were placed inside the 
phosphate buffer saline (PBS) in each individual vial and the gingival fluid was transferred to the vial 
through shaking of the paper cones inside PBS. At the end of each day, the average of 2 samples per 
day were centrifuged in a laboratory at 2500 rpm and temperature of 4°C for 5 minutes and placed in 
a refrigerator at -20°C until all samples were collected for final examination. After taking samples, 
the PGE2 level was measured using ELISA and Abcam method (ab133021 Prostaglandin E2). 
 
Data Analysis 
Data were analyzed using IBM SPSS Statistics for Windows software, version 15 (IBM 
Corp., Armonk, NY, USA). Descriptive statistics were used to calculate the absolute and relative 
frequencies, mean and standard deviation. Kolmogorov-Smirnov and Pearson tests along with t-test 
for independent sample or its non-parametric equivalence Mann-Whitney U Test were used in the 
analyis. In this study, p-value less than 0.05 was considered statistically significant. 
 
 Ethical Aspects 
This research project was approved by the Ethics Research Committee of the Tabriz 
University of Medical Sciences (Protocol No. IR.TBZMED.REC.1395.452). All participants signed 
an informed consent form. 
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Results 
There was no statistically significant relationship between gender of participants and the 
study groups (p<0.05) (Table 1). 
 
Table 1. Distribution of participants according to group. 
 Gender 
Groups Male Female 
 N (%) N (%) 
Case 15 (57.7) 11 (42.3) 
Control 12 (46.2) 14 (53.8) 
 
The Pearson test was used to evaluate the probability of significant statistical relationship 
between PGE2 in case group and pocket depth, FBS and HbA1C of case group (Table 2). There was 
no statistically significant relationship between PGE2 in case group and pocket depth, FBS and 
HbA1C of case group (p > 0.05). 
 
Table 2. Distribution of the Pearson test values. 
Case Group Pearson Correlation p-value 
Periodontal Pocket Depth & PGE2 0.143 0.486 
FBS & PGE2 0.054 0.793 
HbA1C & PGE2 0.199 0.330 
 
The mean and standard deviation of PGE2 variable have been represented in Figure 1. 
According to the results, the mean PGE2 level was higher in the case group compared to the control 
group. 
 
 
Figure 1. Mean curve of PGE2 in case and control groups. 
 
There was no statistically significant relationship between periodontal pocket depth variable 
means in two study groups (p>0.05). There was a significant difference between PGE2 means of two 
study groups and the mean of PGE2 was higher in case group compared to the control group 
(p<0.001) (Table 3). 
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Table 3. Comparision of the studied variables in case and control groups. 
Variables Control Group Case Group p-value 
 Mean (SD) Mean (SD)  
Periodontal Pocket Depth 3.65 ± 0.63 4.14 ± 0.87 0.057 
HbA1  8.22 ± 2.13  
FBS  215.96 ± 124.36  
PGE2 251.31 ± 223.12 640.48 ± 375.58 <0.001 
 
Discussion 
There are some studies about the relation between diabetes mellitus and increase of oral 
diseases [8,9]. The research data established that the higher level of risk of development of 
periodontitis is expected in the diabetic patients whose metabolic control is poor and the destruction 
level is higher [10,11]. 
Similarly, there are also many studies targeted to determine the periodontal status and the 
severity of the periodontal disease in diabetes mellitus patients [8,12-15]. It is showed by many 
researches that the GCF of type 1 diabetes mellitus patients contains more PGE2 levels than non-
diabetic patients [6,16,17]. 
In this study, comparing PGE2 levels in both diabetic and non-diabetic groups showed that 
there was a significant difference between them, in a way that the PGE2 level was higher in diabetic 
people, being in agreement with previous findings [6,16] who recommended that the GCF PGE2 
levels of type 1 diabetes mellitus patients with periodontitis were significantly higher than the non-
diabetic periodontitis patients. A study on investigating of PGE2 and IL-1β and TNFα in diabetic 
periodontal patients showed that diabetes significantly increases the level of PGE2 and IL-1β and 
TNFα from monocytes compared to the non-diabetic patients [6]. It was demonstrated that diabetes 
as a chronic inflammatory disease leads to increased levels of inflammatory cytokines such as PGE2 
in the bloodstream [18]. 
The effect of cyclooxygenase 1 and 2 (COX-1 and COX-2) has been investigated and led to 
this fact that FBS significantly increases the production of PGE2 [19]. In the present study the 
results of investigating the correlation between PGE2 with periodontal pocket depth, HbA1C and 
FBS in the case group showed that there was no correlation between PGE2 level with the 
periodontal pocket depth, HbA1C and FBS. In the contrast, a study on evaluating of the gingival 
fluid in people with oral and systemic diseases concluded that there is higher level of PGE2 in 
gingival fluid of people with type 2 diabetes whose level of HbA1C is more than 8% compared to 
diabetics with HbA1c levels below 8% [20]. The inconsistency of results obtained previously [20] 
and the findings of present study can be due to the sample differences. While a study used people 
undergoing periodontal surgery [20], in the present study we analyzed people with chronic 
generalized periodontitis. 
No significant relationship was previously observed between PGE2 and HbA1C levels [21]. 
Prostaglandin E2 level of gingival fluid with pocket depth in periodontal patients showed that PGE2 
level has a significant relationship with periodontal pocket depth and is increased with its increasing 
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[22,23]. The results obtained with Chinese patients [22] are different from those described in this 
study. Again, the difference between study samples can be also the reason of this inconsistency. 
Chinese patients with different periodontal pocket depths were investigated [22], while we have 
investigated the effect of pocket depth on the level of prostaglandin E2 in people with chronic 
generalized periodontitis with diabetes and all with high periodontal pocket depth. 
The level of gingival fluid PGE2 in type 2 diabetic patients with periodontitis showed that 
diabetes is a risk factor for periodontal disease and there is a correlation between gingival fluid 
PGE2 and periodontal disease severity [24]. 
Strong association between the PGE2 in GCF levels and severity of chronic periodontitis has 
been investigated [25]. The highest concentration of PGE2 in GCF ranged between (7001-8000 
pg/ml) was found in patients diagnosed with generalized severe chronic periodontitis with a 
percentage (13.3%), while 3.3% of patients diagnosed with localized moderate chronic periodontitis 
have the lowest concentrations of PGE2 in GCF, which ranged between (1000-2000 pg/ml) [25]. 
Recently, some studies showed the effect of several drugs (such as melatonin, cyclic NSAID) in 
reduction of PGE 2 for the treatment of periodontitis in healthy and diabetic patients [26-30]. 
Based on our study, since the type 2 diabetes mellitus is a risk factor in the diabetic patients, 
their periodontal control should regularly be done. As an important finding, asymptomatic 
periodontal diseases, which are understood among diabetic persons, can simply be identified. This 
study, which compared the two groups, is not able to propose significant relative between PGE2 and 
action of periodontal disease. Further prespective investigations are necessary to study the 
relationship between the PGE2 in GCF and other inflammatory mediators in patients with chronic 
periodontitis. More research should be conducted in the mechanism by which PGE2 causes 
destruction of periodontal tissue in chronic periodontitis.  
 
Conclusion 
It was determined that the GCF PGE2 level of healthy group is significantly lower than 
diabetes mellitus type 2 group. In this study, there was no statistical relation between the clinical 
parameters and the PGE2 level. 
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